Immunosuppressive co-treatment with Infliximab and adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time.

VIEUJEAN, Sophie; LOUIS, Edouard; REENAERS, Catherine

Poster (Scientific congresses and symposiums)

VIEUJEAN, Sophie; LOUIS, Edouard; REENAERS, Catherine

2018 • 30th edition of Belgian Week of Gastroenterology

Peer reviewed

Permalink
https://hdl.handle.net/2268/236047

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis - IBD Research.pdf

Publisher postprint (1.28 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

General & internal medicine

Author, co-author :

VIEUJEAN, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive

LOUIS, Edouard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive

REENAERS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive

Language :

English

Title :

Immunosuppressive co-treatment with Infliximab and adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time.

Publication date :

February 2018

Event name :

30th edition of Belgian Week of Gastroenterology

Event date :

du 21 février 2018 au 23 février 2018

Peer reviewed :

Peer reviewed

Available on ORBi :

since 28 May 2019

Statistics

Number of views

49 (1 by ULiège)

Number of downloads

17 (0 by ULiège)

More statistics